11 – 20 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
(
- Contribution to journal › Article
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article
-
Mark
Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia
(
- Contribution to journal › Article
- 2017
-
Mark
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
(
- Contribution to journal › Article
-
Mark
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
(
- Contribution to journal › Letter
-
Mark
NOX2-dependent immunosuppression in chronic myelomonocytic leukemia
(
- Contribution to journal › Article
-
Mark
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis
(
- Contribution to journal › Article
- 2016
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
-
Mark
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
(
- Contribution to journal › Article